European Society of Cardiology: cardiovascular disease statistics 2021
Aims This report from the European Society of Cardiology (ESC) Atlas Project updates and
expands upon the widely cited 2019 report in presenting cardiovascular disease (CVD) …
expands upon the widely cited 2019 report in presenting cardiovascular disease (CVD) …
Mendelian randomization: concepts and scope
RC Richmond, GD Smith - Cold Spring …, 2022 - perspectivesinmedicine.cshlp.org
Mendelian randomization (MR) is a method of studying the causal effects of modifiable
exposures (ie, potential risk factors) on health, social, and economic outcomes using genetic …
exposures (ie, potential risk factors) on health, social, and economic outcomes using genetic …
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label …
KK Ray, RPT Troquay, FLJ Visseren… - The Lancet Diabetes & …, 2023 - thelancet.com
Introduction Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran,
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …
European Society of Cardiology: cardiovascular disease statistics 2019
Aims The 2019 report from the European Society of Cardiology (ESC) Atlas provides a
contemporary analysis of cardiovascular disease (CVD) statistics across 56 member …
contemporary analysis of cardiovascular disease (CVD) statistics across 56 member …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation …
Background Circulating lipoprotein lipids cause coronary heart disease (CHD). However,
the precise way in which one or more lipoprotein lipid-related entities account for this …
the precise way in which one or more lipoprotein lipid-related entities account for this …
Time course of LDL cholesterol exposure and cardiovascular disease event risk
Background Incident cardiovascular disease (CVD) increases with increasing low-density
lipoprotein cholesterol (LDL-C) concentration and exposure duration. Area under the LDL-C …
lipoprotein cholesterol (LDL-C) concentration and exposure duration. Area under the LDL-C …
Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
Mendelian randomisation uses genetic variation as a natural experiment to investigate the
causal relations between potentially modifiable risk factors and health outcomes in …
causal relations between potentially modifiable risk factors and health outcomes in …
Evaluating the potential role of pleiotropy in Mendelian randomization studies
Pleiotropy, the phenomenon of a single genetic variant influencing multiple traits, is likely
widespread in the human genome. If pleiotropy arises because the single nucleotide …
widespread in the human genome. If pleiotropy arises because the single nucleotide …
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
When diet and lifestyle are insufficient to attenuate the risk of atherosclerotic cardiovascular
disease, pharmacotherapy is mandated. A global approach that addresses multiple risk …
disease, pharmacotherapy is mandated. A global approach that addresses multiple risk …